(function(){var loadHandler=window['sl_{EC00A760-FAC2-48CD-8603-FA3C7FB92E6B}'];loadHandler&&loadHandler(24, '<div id="spr0_36557d1"><div id="spr1_36557d1" class="kern slide"><img id="img1_36557d1" src="data/img9.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_36557d1" class="kern slide"><img id="img0_36557d1" src="data/img10.png" width="1279.68" height="720" alt=""/><div id="svg3_36557d1" style="left:43.014px;top:107.333px;"><svg width="75" height="221" viewBox="0 0 75 221"><g fill="none"><g><path fill="#203864" d="M74.5,220 L0,159.31 V0 L74.5,60.69 V220 Z" fill-rule="evenodd"/></g></g></svg></div><div id="svg7_36557d1" style="left:43.014px;top:87.952px;"><svg width="43" height="180" viewBox="0 0 43 180"><g fill="none"><g><path fill="#2f5597" d="M42.333,159.351 L0,179.048 V19.213 L42.333,0 V159.351 Z" fill-rule="evenodd"/></g></g></svg></div><div id="svg11_36557d1" style="left:67.681px;top:67.285px;"><svg width="18" height="180" viewBox="0 0 18 180"><g fill="none"><g><path fill="#203864" d="M17.667,179.863 L0,162.264 V0 L17.667,17.76 V179.863 Z" fill-rule="evenodd"/></g></g></svg></div><div id="svg15_36557d1" style="left:1178.289px;top:66.742px;"><svg width="35" height="183" viewBox="0 0 35 183"><g fill="none"><g><path fill="#203864" d="M34.5,162.071 L0,182.925 V20.854 L34.5,0 V162.071 Z" fill-rule="evenodd"/></g></g></svg></div><div id="svg17_36557d1" style="left:67.617px;top:66.742px;"><svg width="1146" height="162" viewBox="0 0 1146 162"><path fill="#4472c4" d="M0,0 h1145.182 v161.833 h-1145.182 Z"/></svg></div><div id="spr3_36557d1" style="left:100.631px;top:84.031px;"><div style="width:0px;"><span id="txt0_36557d1" data-width="1027.890625" style="left:9.6px;top:22.467px;">HTA considerations – emerging payer landscape</span></div></div><div id="spr4_36557d1" style="left:145.122px;top:276.488px;"><div style="width:0px;"><span id="txt1_36557d1" data-width="993.312500" style="left:9.6px;top:-36.624px;">Recent tumour-agnostic approval by the EC/EMA supports further development along these lines. To date, it is not</span></div><div style="width:0px;"><span id="txt2_36557d1" data-width="612.677124" style="left:9.6px;top:-13.584px;">clear how the HTA agencies may evaluate the value of these therapies.</span></div><div style="width:0px;"><span id="txt3_36557d1" data-width="1008.500000" style="left:9.6px;top:22.02px;">For larotrectinib, statements of the GBA and NICE are already published (GBA 2020 (insufficient data of basket trials;</span></div><div style="width:0px;"><span id="txt4_36557d1" data-width="217.906250" style="left:9.6px;top:45.829px;">IQWIQ 2020; NICE 2020).</span></div><div style="width:0px;"><span id="txt5_36557d1" data-width="40.937500" style="left:9.6px;top:81.433px;">NICE</span></div><div style="width:0px;"><span id="txt6_36557d1" data-width="929.902954" style="left:9.6px;top:117.806px;">More evidence on larotrectinib is being collected until there are enough data to address the committee’s</span></div><div style="width:0px;"><span id="txt7_36557d1" data-width="979.027954" style="left:9.6px;top:141.616px;">uncertainties. After this NIxqCE will decide whether or not to recommend it for use on the NHS and update the</span></div><div style="width:0px;"><span id="txt8_36557d1" data-width="636.840454" style="left:9.6px;top:164.656px;">guidance. It will be available through the Cancer Drugs Fund until then.</span></div><div style="width:0px;"><a id="hl0_36557d1" href="https://www.nice.org.uk/guidance/TA630/chapter/1-Recommendations" title="https://www.nice.org.uk/guidance/TA630/chapter/1-Recommendations" target="_blank" onclick="document.getElementById(\'coreSpr_6623461\').getCore().processTriggerEffect(this);return document.getElementById(\'coreSpr_6623461\').getCore().gotoLink(this);"><span id="txt9_36557d1" class="nokern" data-width="431.692719" style="left:9.6px;top:201.805px;">https://www.nice.org.uk/guidance/TA630/chapter/1-Recommendations</span></a></div><div style="width:0px;"><span id="txt10_36557d1" class="nokern relpos" data-width="218.918625" style="left:9.6px;top:230.978px;">Managed access agreement in place </span><a id="hl1_36557d1" class="relpos" href="https://www.nice.org.uk/guidance/ta630/resources/managed-access-agreement-pdf-8767840429" title="https://www.nice.org.uk/guidance/ta630/resources/managed-access-agreement-pdf-8767840429" target="_blank" onclick="document.getElementById(\'coreSpr_6623461\').getCore().processTriggerEffect(this);return document.getElementById(\'coreSpr_6623461\').getCore().gotoLink(this);"><span id="txt11_36557d1" class="nokern relpos" data-width="587.261108" style="left:9.593px;top:230.978px;">https://www.nice.org.uk/guidance/ta630/resources/managed-access-agreement-pdf-8767840429</span></a></div><div style="width:0px;"><span id="txt12_36557d1" data-width="1000.395874" style="left:9.6px;top:258.606px;">Need for an evolved HTA process for site-/tumour-agnostic scenario, i.e., new “rare” diseases being ‘created’ out of</span></div><div style="width:0px;"><span id="txt13_36557d1" data-width="1012.979187" style="left:9.6px;top:282.415px;">many individual conditions through biomarker or genomic subset combi into one larger population (e.g., TRK fusion /</span></div><div style="width:0px;"><span id="txt14_36557d1" data-width="119.229172" style="left:9.6px;top:305.456px;">larotrectinib).</span></div><div style="width:0px;"><span id="txt15_36557d1" data-width="384.270844" style="left:9.6px;top:341.06px;">Trial design/parallel scientific advice for HTA</span></div><div style="width:0px;"><span id="txt16_36557d1" data-width="997.385437" style="left:9.6px;top:377.433px;">Other considerations? E.g., Tumour mutational burden? Observations of increased OS independently of indication?</span></div></div></div></div>', '{"s":[]}');})();